{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-051890","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.341571+00:00","generated_at":"2026-05-28T23:42:17.908280+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos Therapeutics announces $3.5M registered direct offering of 709,220 shares and warrants","bullets":["Gross proceeds of ~$3.5M from 709,220 shares at $4.935 each; warrants exercisable at $4.81 for two years.","Additional ~$3.4M if warrants fully exercised; net proceeds for working capital and general corporate purposes.","H.C. Wainwright receives 7% cash fee, 1% management fee, and placement agent warrants for 49,645 shares at $6.1688.","Closing expected Dec 24, 2024; 45-day lock-up on share issuance and one-year restriction on variable rate transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-051890","json":"https://secwatch.observer/filing/0001493152-24-051890.json","markdown":"https://secwatch.observer/filing/0001493152-24-051890.md","text":"https://secwatch.observer/filing/0001493152-24-051890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224051890/0001493152-24-051890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224051890/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:42:17.908280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}